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 Abstract 
 Background: Brain injury is a medical emergency that 
needs to be diagnosed and treated promptly. Several pro-
teins have been studied as biomarkers of this medical 
condition. The aims of this study were to: 1) evaluate the 
selectivity and precision of a commercial ELISA kit for 
neurofilament medium polypeptide (NFM) protein; and 
2) evaluate the concentration in cerebrospinal fluid (CSF) 
and serum of healthy individuals and patients with brain 
damage. 
 Methods: An ELISA from Elabscience was used. The selec-
tivity was evaluated using size-exclusion chromatography 
and mass spectrometry. Intra- and inter-batch coefficients 
of variation (CV) were also studied. Fifty-one CSF samples 
from 36 age-matched patients with hemorrhagic stroke 
(HS) (n  =  30), ischemic stroke (IS) (n  =  11) and healthy indi-
viduals (n  =  10) were assayed. In addition, serum samples 
from healthy volunteers (n  =  47), 68 serum samples from 
seven patients with HS, 106 serum samples from 12 
patients with traumatic brain injury (TBI) and 68 serum 
samples from 68 patients with mild traumatic brain injury 
(mTBI) were also analyzed. 
 Results: NFM was identified in the chromatographic 
fraction with highest immunoreactivity. The intra- and 
inter-batch CVs were    ≤   10% and    ≤   13%, respectively. The 
CSF-NFM concentration in HS was significantly higher 
(p  <  0.0001) than in IS and controls. Serum NFM con-
centration ranged from 0.26 to 8.57 ng/mL in healthy 
individuals (median  =  2.29), from 0.97 to 42.4 ng/mL in 
HS (median  =  10.8) and from 3.48 to 45.4 ng/mL in TBI 
(median  =  14.7). Finally, 44% of patients with mTBI had 
increased NFM concentration, with significantly higher 
levels (p  =  0.01) in patients with polytrauma. 
 Conclusions: To our knowledge this is the first study 
describing increased NFM levels in CSF and serum from 
patients with brain damage. 
 Keywords:  biomarker;  brain injury;  cerebrospinal fluid; 
 neurofilament;  serum;  stroke. 
 Introduction 
 The term  “ brain injury ” refers to a potentially lethal 
medical condition that includes two major types of brain 
damage: 1) spontaneous, non-traumatic brain injury; and 
2) traumatic brain injury (TBI). The most common cause of 
brain injury is by accidental injury to the head. Approxi-
mately 1.7 million Americans suffer a TBI each year, and 
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75% – 90% of those are classified as mild traumatic brain 
injury (mTBI)  [1] . However, stroke is the most common 
form of non-traumatic brain injury, with 795,000 people 
in the US suffering a new or recurrent stroke each year. 
Ischemic stroke (IS) represents 87% of all stroke cases 
whereas hemorrhagic stroke (HS) accounts for 13% of 
cases  [2] . 
 A brain injury is usually a medical emergency that 
needs to be diagnosed and treated promptly, in order to 
improve the likelihood of patient survival and reduce the 
consequences of brain damage. For this purpose, several 
proteins such as S100 calcium-binding protein B (S100B), 
neuron-specific enolase (NSE) and glial fibrillary acidic 
protein (GFAP) have been proposed as diagnostic and 
prognostic biomarkers of TBI and stroke  [3 – 6] . However, 
given the complexity and heterogeneity of brain injury eti-
ology, none of these proteins seem to be useful in these 
patients as single biomarkers. Therefore, it has been sug-
gested that integrated panels of biomarkers with specific 
and complementary characteristics may assist in the diag-
nosis, risk assessment, treatment selection and prediction 
of clinical outcomes of patients with brain damage. 
 In our previous study  [7] , we identified three novel 
biomarkers of brain injury: neurofilament medium pol-
ypeptide (NFM),  α -internexin ( α -Inx) and  β -synuclein 
( β -Syn) in the cerebrospinal fluid (CSF) of patients with 
HS, by using a mass spectrometry-based assay. The aim 
of the current work was to perform a verification study of 
one of these biomarkers using a more sensitive analytical 
assay. The protein selected was NFM for three reasons: 
1) given its novelty (to our knowledge this is the first 
study evaluating NFM as biomarker of brain injury); 2) 
the other two members of its family, neurofilament light 
and heavy polypeptides (NFL and NFH), have also been 
studied and identified as potential biomarkers of HS  [8 –
 11] ; and 3) there was a commercial ELISA kit available, 
with enough sensitivity (low pg/mL level) to detect this 
protein in CSF and blood samples of patients with brain 
damage. 
 Before we assayed NFM protein in biological samples 
from patients with brain injury, the commercial ELISA kit 
was validated, since we and others have drawn attention 
to the rapid dissemination of ELISA kits of questionable 
quality from various manufactures  [12, 13] . 
 Therefore, the aims of this study were to: 1) evaluate 
the selectivity (using size-exclusion chromatography and 
mass spectrometry) and precision of a commercial ELISA 
kit for NFM protein; and 2) evaluate the concentration of 
this protein in biological fluids (CSF and serum) of healthy 
individuals and patients with brain injury (stroke, TBI and 
mTBI). 
 Materials and methods 
 ELISA kit for NFM protein 
 A commercial ELISA kit [Human Neurofi lament 3 (NEF3); Catalog No: 
E-EL-H0740; from Elabscience Biotechnology Co., Ltd] was used to 
measure NFM protein in various biological fl uids. The ELISA kit uses 
capture and secondary monoclonal antibodies from rat and whole pro-
tein (natural, purifi ed protein) as standard material, according to the 
information provided by the manufacturer. The reported limit of detec-
tion is 9.4 pg/mL; with an analytical measurement range from 15.6 to 
1000 pg/mL. The intra-batch coeffi  cient of variation (CV) is below 10%. 
The assay was performed according to the manufacturer ’ s instructions. 
 Size exclusion high-performance liquid chromatography 
(SE-HPLC) 
 The SE-HPLC was performed using 0.1 M NaH 2 PO 4 /Na 2 HPO 4 , 0.15 M 
NaCl (pH 7.0) buff er at a fl ow rate of 0.5 mL/min for 60 min with a gel 
fi ltration column TSKgel G3000SW, 7.5 mm (ID) x 60 cm (L), 10   μ m 
(Tosoh Bioscience, King of Prussia, PA, USA). Liquid chromatogra-
phy was performed in a HPLC 1100 series (Agilent Technologies) with 
diode array detector (DAD), set at 254 nm (UV lamp). The system was 
controlled with ChemStation soft ware (Agilent Technologies). One 
hundred microliters of each sample (100  μ L loop) were loaded into 
the column. Proteins contained in four diff erent samples (NFM stand-
ard from ELISA kit, brain tissue extract from previous study  [7] , CSF 
sample from patient with HS and no blood contamination and serum 
sample from healthy individual) were subjected to chromatographic 
separation. Fractions (0.5 mL) were collected every minute, from 18 
to 58 min, aft er the isocratic fl ow was started. The same volume of a 
Gel Filtration Standard (Catalog 151-1901, Bio-Rad Laboratories) was 
loaded before samples. 
 Mass spectrometry identifi cation 
 Three SE-HPLC fractions from brain tissue extract were analyzed in 
an LTQ Orbitrap XL (Thermo Scientifi c). Samples volume was reduced 
from 400 to 50  μ L using a SpeedVac concentrator (Savant SC250EXP, 
Thermo Scientifi c) and then processed as described previously  [7] . 
Briefl y, proteins were denatured, reduced, alkylated and trypsin 
digested. Peptides were analyzed by liquid chromatography coupled 
to tandem mass spectrometry (LC-MS/MS), and the resulting spectra 
were searched separately against the Human UniprotKB-SwissProt 
Database 2013_10 (containing 88266 forward protein sequences) by 
Mascot soft ware (version 2.2, Matrix Science). 
 Intra- and inter-batch CV of NFM ELISA kit 
 Serum samples from six healthy volunteers were diluted 1:20 and 
used to study the precision of NFM ELISA kit. Four samples (named 
QC1 to 4) were analyzed six times with the same ELISA kit to calculate 
the CV intra-batch. The other two samples (named QC5 and 6) were 
measured eight times with fi ve ELISA kits from three diff erent lots to 
calculate the CV inter-batch. 
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Network and the Lunenfeld-Tanenbaum Research Institute (Toronto), 
with informed consent. 
 Serum samples from patients with hemorrhagic stroke 
 Seventy-eight serum samples from seven patients admitted to St. 
Michael ’ s Hospital (Toronto) with SAH were used for the analysis 
of NFM. Samples were obtained as soon as possible aft er admis-
sion of individuals to the intensive care unit and during therapy, for 
4 – 13  days. Between 7 and 12 samples from each patient were ana-
lyzed, which were stored at  – 80  ° C until assayed. These were samples 
from a previous study  [14] for which a frozen aliquot was available. 
Ethics approval for the collection of samples was obtained from the 
Institutional Review Board of St. Michael ’ s Hospital. 
 Serum samples from patients with TBI 
 A total of 106 serum samples from 12 patients with severe TBI admit-
ted to the surgical intensive care unit at National University Hospital 
(Singapore) for medical or emergency surgical management of their 
brain injury were used for analysis of NFM protein concentration. 
These were serum samples from patients (4 female and 8 male), aged 
21 – 78 years, recruited for a previous study  [15] . Outcome at 3 months 
aft er injury was assessed using the Glasgow Outcome Score (GOS). 
Research board ethics approval (Singapore DSRB project 2010/00286) 
was obtained before the study commenced. 
 Serum samples from patients with mTBI 
 Serum samples were collected from 68 patients aged 15 – 84 years (27 
females and 41 males), presenting at the emergency department of 
the Academic Hospital of Parma (Italy) with a history of mTBI in the 
previous 6 h, and Glasgow Coma Score (GCS) of 14 – 15 at presentation. 
Patients fulfi lled the criteria for mTBI requiring computed tomogra-
phy (CT) scanning according to local guidelines. The peritraumatic 
amnesia was determined by the patient ’ s ability to recall events they 
can remember immediately before and aft er the injury. Inclusion cri-
teria were the same as those described in a previous study  [16] . Ethics 
approval for the collection of samples was obtained from the local 
committee. 
 Statistical analysis 
 Statistical analysis was performed using the IBM SPSS Statistic soft -
ware, version 20. A p-value   <  0.05 was considered statistically signifi -
cant. Normal distribution was evaluated using Shapiro-Wilk test and 
by inspection of Q-Q plots. Student ’ s t- or Mann-Whitney U-tests were 
performed for comparisons between two groups. Kruskal-Wallis test 
was performed for comparisons between more than two groups. Asso-
ciations between variables were assessed by Spearman ’ s rank corre-
lation coeffi  cient. Reed ’ s test was used for identifi cation of outliers. 
 This study was conducted according to the World Medical Asso-
ciation Declaration of Helsinki regarding ethical conduct of research 
involving human subjects and/or animals. 
 Sample collection 
 A total of 51 CSF samples from 36 individuals and 299 serum samples 
from 134 individuals were collected for this study ( Table 1 ). 
 CSF samples from patients with stroke and healthy 
controls 
 Fift y-one samples from 36 age-matched patients were retrospectively 
selected from a CSF biobank at the Department of Clinical Biochemis-
try, Hospital Universitario Central de Asturias (HUCA), Spain, includ-
ing samples from individuals with HS (n  =  30), IS (n  =  11) and healthy 
individuals (n  =  10). Some of these samples (n  =  36) were used in our 
previous study  [7] for the identifi cation of proteins (including NFM) 
elevated in the CSF of patients with HS. CSF samples were collected 
a few days aft er symptoms onset [median, (minimum-maximum)]: 5 
(0 – 9) days in HS group and 1 (0 – 3) day in IS group. 
 Sample aliquots were prepared and stored at  – 80  ° C until 
assayed. Ethics approval for sample collection was obtained from the 
institutional review board of HUCA. 
 Briefl y, patients with HS (n  =  15) were diagnosed with intracer-
ebral hemorrhage (ICH) (n  =  7) or subarachnoid hemorrhage (SAH) 
(n  =  8). Control individuals (n  =  10) were diagnosed with benign 
headache, mild cognitive impairment, depression and other non- 
neurological diseases. CSF samples from controls and IS patients 
had    ≤   3 white blood cells (WBC)/mm 3 (except for one IS patient with 
6 WBC/mm 3 ) and negative xanthochromia. 
 NFM protein was also measured in 19 serial samples (n  =  6, 3, 5 
and 5 samples, respectively) from four patients with HS (ICH, n  =  2; 
SAH, n  =  2). These CSF samples were collected between 2 and 41 days 
aft er symptoms onset. 
 Serum samples from healthy volunteers 
 Serum samples from healthy 47 volunteers, 26 women and 21 men, 
between 17 and 57 years old were collected to establish the reference 
range for NFM. Individuals were recruited at the University Health 
 Table 1   CSF (n  =  51) and serum samples (n  =  299) collected from 170 
individuals. 
Samples, n   Patients, n   Diagnosis 
CSF, n    
   10   10  Control
   11   11  Ischemic stroke (IS)
   30   15 a   Hemorrhagic stroke (HS)
Serum, n    
   47   47  Healthy individual
   78   7 b   Subarachnoid hemorrhage (SAH)
   106   12 c   Traumatic brain injury (TBI)
   68   68  Mild traumatic brain injury (mTBI)
 a 11 patients had only one sample and 4 patients had 6, 3, 5 and 5 
samples (see Figure 1). Only the first sample of these four patients 
is displayed in Figure 1;  b See  Table 2 ;  c See  Table 3 . 
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 Results 
 SE-HPLC 
 One hundred microliters of four samples (NFM stand-
ard from ELISA kit, brain tissue extract, CSF and serum) 
were injected. The SE-HPLC fractions from each sample 
(from 18 to 58 min) were analyzed with the ELISA kit for 
NFM protein. The four samples analyzed showed the 
highest immunoreactivity for NFM protein in fractions 
23 and 24 (Supplemental Data, Figure S1, that accom-
panies the article  http://www.degruyter.com/view/j/
cclm.2015.53.issue-10/cclm-2015-0908/cclm-2015-0908.
xml?format=INT ), in agreement with the molecular weight 
of this protein (about 160 kDa). 
 Mass spectrometry identification 
 Three SE-HPLC fractions from brain tissue extract (frac-
tions 18, 23 and 34) were analyzed by LC-MS/MS. A tryptic 
peptide from NFM protein was exclusively identified in 
fraction 23 (Supplemental Data, Figure S2). These results 
agreed with the results obtained with the ELISA kit, con-
firming the presence of NFM protein in the fraction with 
the highest ELISA immunoreactivity. 
 Linearity and intra- and inter-batch CV 
of NFM ELISA kit 
 The ELISA kit showed good linearity between 15.6 and 
500  pg/mL (Supplemental Data, Figure S3). CSF and 
serum samples had to be diluted (from 1:1 to 1:1000) before 
analysis using the diluent provided in the ELISA kit. 
Samples were analyzed in duplicate but at two different 
dilutions (1:10 and 1:100 for CSF and serum from healthy 
volunteers and 1:50 and 1:100 for serum from patients with 
brain injury). If NFM concentration was above or below 
the linear range in both dilutions, samples were analyzed 
again with higher or lower dilutions. 
 Four samples (QC 1 – 4) with different concentra-
tions of NFM protein were analyzed six times with the 
same ELISA kit. The concentration (mean ± SD) and the 
 intra-batch CV were: QC1: 20 ± 2  pg/mL (CV  =  9%); QC2: 
90 ± 4 pg/mL (CV  =  5%); QC3: 198 ± 16 pg/mL (CV  =  8%); and 
QC4: 405 ± 39 pg/mL (CV  =  10%). 
 Two samples (QC 5 – 6) with low and high concentra-
tions of NFM protein were analyzed eight times with five 
ELISA kits from three different lots. The concentration 
(mean ± SD) and the inter-batch CV were: QC5: 74 ± 9 pg/mL 
(CV  =  12%); and QC6: 314 ± 41 pg/mL (CV  =  13%). 
 CSF samples from patients with stroke and 
healthy controls 
 The concentration of NFM protein in the CSF samples 
from patients with ICH (n  =  7), SAH (n  =  8), IS (n  =  11) 
and controls (n  =  10) was, respectively, (median and 
minimum-maximum): 10.6 (4.78 – 373) ng/mL, 5.66 
(0.43 – 131) ng/mL, 0.21 (0.07 – 1.36) ng/mL and 0.23 (0.11 –
 0.62)  ng/mL. These results agreed with those obtained 
with the mass spectrometry-based assay, because 
both analyses showed statistically significant differ-
ences between the HS group and the other two groups 
( Figure 1 A). When combined, the NFM concentration in 
the HS group was significantly higher than the concen-
tration in the IS and control groups (p  <  0.0001). There 
were no significant differences between the IS and 
control groups (p  =  0.86). The p-values obtained with 
the NFM results from ELISA are lower because this assay 
has higher sensitivity than the mass spectrometry-based 
assay. The analysis of serial samples from four of these 
patients revealed that the highest NFM concentration 
was observed between 8 and 11 days after onset of symp-
toms ( Figure 1 B). 
 The seven patients with ICH showed secondary intra-
ventricular hemorrhage (IVH). Four of these patients had 
an unfavorable outcome (GOS 1 – 2) and three had a favora-
ble outcome (GOS 3 – 4). Five out of the eight patients with 
SAH had Fisher grade 4 scans [GOS 1 (n  =  2) and GOS  3 
(n  =  3)] whereas the CT scan confirmed the absence of 
IVH in the other three patients [GOS 4 (n  =  1) and GOS 5 
(n  =  2)]. The three patients with CSF NFM concentration 
  >  100  ng/mL ( Figure  1 A) were some of the patients who 
finally died (GOS  1). However, the three patients with 
NFM concentration lower than 1 ng/mL had a favorable 
outcome [GOS 3 (n  =  1) and GOS 5 (n  =  2)]. 
 Serum NFM concentration in healthy 
individuals 
 NFM concentration was analyzed in serum samples 
from 47 apparently healthy volunteers (26 women 
and 21  men). The NFM concentration was from 0.26 to 
27.8  ng/mL. The highest concentration corresponding 
to a 35-year-old man (27.8 ng/mL) was identified as an 
outlier (according to the Reed ’ s test) and excluded from 
subsequent analyses. Therefore, the NFM concentration 
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in the 46 remaining individuals was from 0.26 to 
8.57 ng/mL, being this  interval used as reference range 
for subsequent analysis. We found no significant asso-
ciation between serum NFM concentration and age 
(Spearman ’ s ρ  =  0.20, p  =  0.18). However, there was a 
highly significant difference in NFM levels between men 
and women (p  <  0.001). The NFM levels were (median 
and minimum-maximum): 1.36 (0.26 – 6.40)  ng/mL in 
women (n  =  26); and 4.43 (0.76 – 8.57)  ng/mL in men 
(n  =  20). There were no significant differences in age 
between both genders (p  =  0.55); with an average age 
(and standard deviation): 38.4 ± 9.9 years (females) and 
36.7 ± 9.5 years (males). 
 Serum samples from patients with 
 hemorrhagic stroke 
 Serial serum samples (n  =  78) from seven patients with 
SAH were measured. NFM levels ranged from 0.97 to 42.4 
ng/mL ( Table 2 ). The median of initial NFM concentration 
(5.08 ng/mL) for seven patients with SAH was higher but 
not statistically significant (p  =  0.09) than the median NFM 
concentration in healthy individuals (2.29 ng/mL, n  =  46). 
 Six patients (except patient 5) had at least one sample 
with NFM concentration above the upper reference limit 
(8.57 ng/mL). The two patients who died (GOS 1) showed 
NFM levels above 35 ng/mL prior to death ( Figure  2 A). 
 Figure 1   NFM concentration in 36 CSF samples from patients with ICH (n  =  7), SAH (n  =  8), IS (n  =  11) and controls (n  =  10) according to the 
mass spectrometry-based assay (in fmoles/ μ L; left) and the ELISA kit (in ng/mL; right) (A). 
 NFM concentration in 19 serial CSF samples from four patients with ICH (n  =  2) and SAH (n  =  2) (B). F, female; M, male; MS, mass spectrom-
etry. Age in parentheses. 
Brought to you by | Complejo Asistencial de Salamanca
Authenticated
Download Date | 8/7/15 10:00 AM
6      Mart í nez-Morillo et al.: NFM concentration is increased in brain injury
 Table 2   Time of blood sample collection and NFM concentration (ng/mL) in patients with SAH.  
Patient   Gender   Age, 
years 
  Time of first 
sample, h 
  Time of final 
sample, h 
  Samples, n   Initial NFM 
value, ng/mL 
  NFM Median 
(minimum – maximum) 
  Outcome 
1  Male   48  0  307  16  5.08  31.9 (5.08 – 42.4)  GOS 1
2  Female   50  0  54  7  1.66  1.69 (1.28 – 35.6)  GOS 1
3  Female   63  0  296  11  6.21  9.81 (6.21 – 30.6)  GOS 3
4  Female   50  11 a   299  12  3.48  3.93 (2.96 – 9.47)  GOS 4
5  Male   56  0  316  11  0.97  2.02 (0.97 – 8.57)  GOS 4
6  Male   68  0  242  10  10.96  12.2 (11.0 – 32.6)  GOS 5
7   Male   35   0   170   11   9.22   16.3 (9.22 – 19.0)   GOS 5 
 a There was not any serum left of the first sample of patient 4. 
 Figure 2   Evolution of NFM concentration in serial serum samples from seven patients with SAH (A) and 12 patients with TBI (B). 
 Patients with unfavorable outcome (GOS 1 – 2) are represented with continuous lines while patients with favorable outcome (GOS 3 – 5) are 
represented with broken lines. 
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Patient 1 showed the highest levels of NFM, with a peak 
of 42.4 ng/mL, a few hours after he presented with 
 unreactive pupils and was diagnosed with brain death. 
NFM concentration in Patient 2 increased from 2.56 to 
35.6 ng/mL in   <  16 h and just after she suffered an infarc-
tion of median brain artery. 
 Serum samples from patients with severe TBI 
 Serial serum samples (n  =  106) from 12 patients with 
severe TBI were also measured. NFM levels were from 
3.48 to 45.4  ng/mL ( Table 3 ). The median of initial NFM 
concentration (13.3 ng/mL) for 12 patients with TBI was 
significantly higher (p  <  0.001) than the median NFM con-
centration in healthy individuals (2.29 ng/mL, n  =  46). All 
patients showed at least one sample with NFM concentra-
tion above the upper reference limit ( Figure 2 B). Patients 
with unfavorable outcome (GOS 1 – 2) showed slightly 
higher levels (medians from 10.0 to 34.8 ng/mL) than 
patients with favorable outcome (GOS 3 – 4) (medians from 
7.45 to 15.5 ng/mL). Seven out of these 12 patients (4 with 
a favorable outcome and 3 with an unfavorable outcome) 
had an initial value higher than the upper reference limit. 
The median of initial NFM concentration (20.4 ng/mL) 
for six patients with unfavorable outcome (GOS 1 – 2) was 
higher but not statistically significant (p  =  0.18) than the 
median of initial NFM concentration (8.30 ng/mL) for six 
patients with favorable outcome (GOS 3 – 4). 
 Serum samples from patients with mTBI 
 NFM protein concentration was also analyzed in 68 
patients with mTBI. One sample from each patient was 
collected within 6 h of accident. NFM levels were from 0.21 
to 202.2 ng/mL. Median NFM concentration in patients 
with mTBI (7.89 ng/mL, n  =  68) was significantly higher 
(p  <  0.001) than median NFM concentration in healthy 
individuals (2.29 ng/mL, n  =  46). 
 In total 30 out of 68 (44%) of patients with mTBI had 
a NFM concentration higher than the upper reference 
limit ( Figure 3 ). A total of 34% (14 out of 41) of patients 
with negative CT scan (for hemorrhage or any other sug-
gestive brain abnormality) and no polytrauma ( – / – ) had a 
NFM concentration higher than the upper limit. However, 
69% (11 out of 16) of patients with negative CT scan and 
polytrauma ( – / + ) had a NFM concentration higher than 
the upper reference limit. NFM concentration was sig-
nificantly higher (p  =  0.01) in the group of patients with 
polytrauma ( – / + ) than in the group of patients without 
polytrauma ( – / – ). Finally, 45% (5 out of 11) of patients 
with positive CT scan (with and without polytrauma) ( + / + , 
 + / – ) had a NFM concentration higher than the upper 
reference limit. The median NFM concentration in these 
three groups of patients with mTBI (displayed below) 
was significantly higher than the median NFM concentra-
tion in healthy individuals [Kruskal-Wallis (four groups), 
p  <  0.0001; Mann-Whitney U, group ( – / – ): 5.59 ng/mL, 
p  =  0.001; group ( – / + ): 17.68 ng/mL, p  <  0.001; group ( + / + , 
 + / – ): 7.88 ng/mL, p  =  0.002]. 
 Discussion 
 Human NFM is a 916 amino acid protein with a molecu-
lar mass of approximately 160 kDa, encoded by the  NEFM 
gene, which is located on chromosome 8 (8p21)  [17] . 
 Neurofilaments (NFs) are type IV intermediate fila-
ments (IFs) expressed under three different subunit 
 Table 3   Time of blood sample collection and NFM concentration (ng/mL) in patients with severe TBI. 
Patient   Gender   Age, 
years 
  Time of first 
sample, h 
  Time of final 
sample, h 
  Samples, n   Initial NFM 
value, ng/mL 
  NFM Median 
(minimum – maximum) 
  Outcome 
(3 months) 
1  Male   39  7  99  5  3.48  15.4 (3.48 – 20.9)  GOS 1
2  Male   23  8  128  10  19.4  14.8 (10.6 – 21.9)  GOS 1
3  Male   24  8  44  4  6.35  10.0 (6.35 – 12.9)  GOS 1
4  Female   78  10  118  10  21.4  23.3 (17.3 – 34.1)  GOS 1
5  Female   68  12  121  10  37.8  34.8 (31.1 – 40.9)  GOS 2
6  Female   75  44  144  8  28.4  20.9 (14.1 – 28.4)  GOS 2
7  Female   47  48  157  10  18.2  17.2 (14.0 – 24.0)  GOS 3
8  Male   25  14  122  10  4.79  8.50 (4.79 – 14.3)  GOS 4
9  Male   62  20  127  9  3.94  15.5 (3.94 – 45.4)  GOS 4
10  Male   34  22  130  10  5.09  7.45 (5.09 – 10.7)  GOS 4
11  Male   21  58  154  9  11.5  13.0 (10.9 – 20.9)  GOS 4
12   Male   26   61   181   11   15.1   11.9 (6.70 – 18.8)   GOS 4 
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proteins, NFL, NFM and NFH. NFs and  α -internexin are 
the major protein components of IFs in the central nervous 
system  [18] . NFs (diameter: 8 – 10 nm) are exclusively 
expressed in neurons and act with microtubules (dia-
meter: 24 – 26 nm) and microfilaments (diameter: 6 – 8 nm) 
to form and maintain the axonal structural integrity and 
neuronal shape, establishing a very stable tubular system 
of the neuronal cytoskeleton. NFs also participate to the 
axonal mechanisms of transport  [17, 18] . 
 NFs can be released in the interstitial fluid after axonal 
injury or degeneration due to the disruption of the axonal 
cytoskeleton, and diffuse into CSF, where they can be 
measured to monitor axonal degeneration. NFL and NFH 
proteins have been studied by many authors as markers 
of axonal degeneration in CSF and blood of patients suf-
fering from various neurological diseases. Thus, axonal 
degeneration is thought to be an underestimated com-
plication of SAH, which can continue for days after the 
primary injury, and extend into the period of delayed cer-
ebral ischemia  [17] . Several authors  [8, 9] have reported 
increased CSF levels of these two proteins (NFL and NFH) 
in patients with SAH. Kuhle et al. reported that NFH levels 
in patients with SAH (n  =  20) were from 8.4 to 997 pg/mL 
(median  =  345 pg/mL), while NFH concentration in con-
trols (n  =  73) was from 10 to 100 pg/mL. Similarly, Zanier 
 Figure 3   NFM concentration in 68 serum samples from patients 
with mTBI. 
 Patients were divided into three groups: ( – / – ), negative CT scan 
and no polytrauma; ( – / + ), negative CT scan and polytrauma, ( + / + , 
 + / – ); positive CT scan with and without polytrauma. Vertical lines 
represent the median NFM concentration. 
et al. reported increased NFL levels in patients with SAH 
(n  =  35), from 60 to 2688  pg/mL (median  =  643 pg/mL), 
while NFL concentration in controls (n  =  13) was below the 
limit of detection (  <  12 pg/mL). 
 More recently, Kuhle et  al.  [19] studied serum NFL 
as a predictive biomarker of clinical outcome in patients 
with spinal cord injury, showing a correlation between 
NFL concentration and acute severity and neurological 
outcome. Gaiottino et al.  [20] found increased serum NFL 
concentration in various neurological diseases, with NFL 
levels more than 20-times higher in patients with amyo-
trophic lateral sclerosis than in controls. 
 Cai et  al.  [21] studied the correlation between plas-
matic concentration of phosphorylated NFH (pNFH) 
and clinical outcome or early neurological deteriora-
tion of patients with ICH, showing that plasmatic values 
of pNFH were increased in ICH patients compared to 
healthy individuals (700 pg/mL, n  =  112 vs. 26 pg/mL, 
n  =  112), and that plasma pNFH levels predicted clinical 
outcomes and early neurological deterioration with high 
sensitivity and specificity. The pNFH protein has also 
been proposed as biomarker of axonal injury in multiple 
sclerosis  [22] . 
 To our knowledge this is the first study describing 
increased concentrations of NFM protein in CSF and 
serum samples from patients with brain damage (HS, SAH 
and mild and severe TBI). 
 Here, we have shown that NFM is released into the CSF 
compartment after HS, both in ICH and SAH. However, 
NFM concentration was not significantly elevated in the 
CSF of individuals with IS. Compared to previous studies 
where CSF levels of NFL and NFH proteins were measured 
 [8, 9] , NFM seems to be present at higher concentrations 
in patients with HS (0.43 – 373 ng/mL). Moreover, CSF-NFM 
levels of four patients with HS showed a concentration 
peak several days (between 8 and 11 days) after symptoms 
onset. 
 We also observed that NFM was released and detected 
in greater concentrations in serum samples from two 
patients with SAH that suffered a brain infarction and 
brain death few hours before serum sampling. However, 
NFM levels in patients with SAH seemed not to correlate 
with outcome. 
 Serum samples from patients with severe TBI showed 
also increased NFM levels, with 58% (7 out of 12) of patients 
(67% of patients with GOS 1 – 2 and 50% of patients with 
GOS 3 – 4) showing an initial NFM value higher than the 
upper reference limit (8.57 ng/mL). Moreover, 83% (10 out 
of 12) of patients (100% of patients with GOS 1 – 2 and 67% 
of patients with GOS 3 – 4) showed NFM concentrations 
higher than the upper reference limit ( Table 3 ). 
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 Finally, 44% of patients with recent mTBI (within 6 h 
of sampling) showed increased serum NFM levels with 
significantly higher concentrations in patients with pol-
ytrauma but not in patients with positive CT scan. These 
results may indicate that NFM protein is released from 
other parts of the body apart from the brain since patients 
with polytrauma showed very high serum concentrations. 
This is probably related to the specific expression of NFM 
in neuronal cells and ganglia. According to the informa-
tion provided by the Human Protein Atlas ( http://www.
proteinatlas.org )  [23] , NFM expression at protein level 
(based on immunohistochemistry results) is specific of 
neuronal cells. This protein is highly expressed in central 
nervous system (about 0.2  μ g/mg total protein in our brain 
tissue extracts) but it also shows expression in peripheral 
nervous system (peripheral neurons of peripheral nerve 
and ganglia). Therefore, the elevation of serum NFM con-
centration in polytrauma could be the consequence of a 
peripheral nerve injury (in neurons outside of the brain 
and spinal cord). 
 One of the limitations of this study is that paired CSF 
and serum samples from patients with brain injury were 
not collected and analyzed. The CSF samples used in our 
previous study  [7] for identification of novel biomarkers 
of brain injury were reanalyzed with the NFM ELISA kit 
in order to confirm the results obtained with the mass 
spectrometry-based method. New prospective validation 
studies should be performed to elucidate the kinetics of 
NFM protein in central and peripheral nervous system 
after a brain injury. Another aspect that would be neces-
sary to reproduce in an independent study is the differ-
ences observed in the serum NFM concentrations among 
genders. 
 Conclusions 
 In the present study, we have shown that NFM protein 
concentration is increased in CSF and in blood circulation 
after a brain injury, with higher levels in patients suffering 
HS and polytrauma. More studies are needed to elucidate 
the potential of this protein in the diagnosis, prognosti-
cation and management of patients with brain injury and 
other neurological diseases with axonal degeneration. 
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